AbbVie and J&J claim new Imbruvica okay in US
Blockbuster likely to face cheap near-copy for first time.
AbbVie blood cancer drug tipped to be a blockbuster.
Leukaemia drug likely to get conditional approval.
NICE uncertain over survival data for Gazyvaro and bendamustine.
Development partner Genmab says drug approved in relapsed disease.
Venetoclax still under review in Europe.